Top Pharmaceutical Companies in Detroit, MI (6)
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
Marathon Petroleum Corporation (MPC) is a leading, integrated, downstream energy company headquartered in Findlay, Ohio. The company operates the nation's largest refining system. MPC's marketing system includes branded locations across the United States, including Marathon brand retail outlets. MPC also owns the general partner and majority limited partner interest in MPLX LP, a midstream company that owns and operates gathering,...
Marathon Petroleum Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Quarterly revenue showed sharp momentum, with Q2 reaching approximately $52.3 billion versus roughly $34.1 billion a year earlier, while trailing 12-month trends point toward robust expansion as demand and utilization rebound.
Profitability: Earnings and profitability exceeded expectations, including Q2 EPS of $17.73 and full-year 2025 net income of $4.0 billion with adjusted EBITDA of $12.0 billion, supported by high crude capacity utilization near 94–95%.
Strategic Partnerships: Midstream expansion via MPLX underpins structural growth, with a $2.4 billion organic growth capital plan focused on natural gas and NGL infrastructure and expected distribution growth supporting dividends and capital spending.
DM Clinical Research is a multi-therapeutic network of clinical trial investigator sites headquartered in Houston, Texas. Founded in 2006, the company connects patients with trusted physicians to conduct cutting-edge research focused on quality and compassion, aiming to deliver advanced, preventative medicine to underserved communities. They operate a national network of dedicated research centers and physician-embedded sites throughout the United States.
BioIVT supplies human and animal biospecimens, including tissues, cells and biofluids, alongside ADME-Tox products and specialized research services. Its samples and models support biomedical research, drug discovery and development, diagnostic development, and precision medicine research. By pairing biological materials with clinical donor data, the company helps pharmaceutical, biotechnology, academic and diagnostic researchers investigate disease, assess drug metabolism and toxicity, and...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
ProPharma's Top Stability & Growth Strengths
Market Expansion: Feedback suggests the company is broadening its global footprint, including opening a new office in Hyderabad and expanding across Central and Eastern Europe via acquisitions. These moves indicate a focus on scaling operations and accessing new markets.
Strategic Partnerships: Feedback suggests targeted acquisitions such as Clinres Farmacija and Digital Lab Consulting are used to enhance capabilities and geographic reach. These integrations appear to strengthen end-to-end service coverage across regulatory, clinical, and R&D functions.
Strong Brand Reputation: Feedback suggests multiple industry awards and recognitions, including CPHI and CRO Leadership distinctions, bolster standing as a top-tier provider. External analyst mentions, such as Everest Group’s PEAK Matrix designation, reinforce credibility.
CSL Plasma is one of the world’s largest collectors of human plasma. We are committed to excellence and innovation in everything we do. Our work ensures that tens of thousands of people with rare and serious diseases are able to live normal, healthy lives. We are committed to our work because people’s lives depend on us. See our community guidelines:...









